A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

MLA

Peihua Lu, et al. “A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL).” Blood, vol. 136, Nov. 2020, pp. 14–15. EBSCOhost, https://doi.org/10.1182/blood-2020-136833.

APA

Peihua Lu, Xin Lin, Jingjing Li, Lemei Jia, Junfang Yang, Yanze Shi, Wang Jiasheng, Hongli Zheng, Xian Zhang, Gailing Zhang, Shulian Xia, Jiujiang He, Wenqian Li, Dan Song, Liu Yue, Min Zhang, & Zhi-xiao Zhou. (2020). A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 136, 14–15. https://doi.org/10.1182/blood-2020-136833

Chicago

Peihua Lu, Xin Lin, Jingjing Li, Lemei Jia, Junfang Yang, Yanze Shi, Wang Jiasheng, et al. 2020. “A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL).” Blood 136 (November): 14–15. doi:10.1182/blood-2020-136833.